Download PDF
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes 2022; 130(04): 229-236
DOI: 10.1055/a-1540-5009
Article

Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients

Marta Ragonese
1   Department of Human Pathology DETEV, University of Messina, Messina, Italy
,
Gianluca Di Bella
2   Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
,
Federica Spagnolo
3   Unit of Endocrinology, University of Messina, Messina, Italy
,
Loredana Grasso
4   Service of Immunometry and Laboratory Diagnosis, University Hospital “G. Martino”, Messina, Italy
,
Angela Alibrandi
5   Department of Economics, University of Messina, Messina, Italy
,
Guiseppe Giuffrida
2   Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
,
Mariacarla Moleti
2   Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
,
Francesco Ferraù
1   Department of Human Pathology DETEV, University of Messina, Messina, Italy
,
Salvatore Cannavò
1   Department of Human Pathology DETEV, University of Messina, Messina, Italy
› Author Affiliations Funding The study was supported by the project PRIN 2015 (number 2015ZHKFTA) of the Italian Ministry of Education, University and Research, through research grants.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Acromegaly is associated with an increased risk of fatal and non-fatal cardiovascular (CV) events. Controlling acromegaly decreases, but does not normalize this risk. Brain natriuretic peptide (BNP) assessment is used in the general population for the diagnosis of heart failure and to predict ischemic recurrences and mortality. This is a retrospective, longitudinal, monocenter study that evaluates the role of serum N-terminal fragment of BNP (NT-pro-BNP) for predicting CV events in acromegaly patients.

Methods Serum NT-pro-BNP levels were measured in 76 patients with acromegaly (23 males, 57.7±1.5 years), and compared with other predictors of CV events. NT-pro-BNP cut-off value discriminating the occurrence of CV events was determined by ROC analysis. CV events were recorded during a follow-up of 78.6±6.4 months.

Results CV events occurred in 9.2% of patients. Mean log(NT-pro-BNP) concentration was higher in patients who experienced CV events than in those who did not (p<0.01) and in patients who died due to CV events than in those who died due to other causes (p<0.01). Based on the ROC curve, a cut-off value of 91.55 pg/mL could predict CV events (OR 19.06). Log(NT-pro-BNP) was lower in surgically treated patients by surgery (p<0.05), and in those cured by neurosurgery (p<0.02).

Conclusions High NT-pro-BNP value is an independent middle-term predictor of fatal or non-fatal CV events in patients with acromegaly. According to this parameter, surgically treated patients show lower CV risk than those managed with medical therapy, especially if the disease is cured.

Key words

NT-pro-BNP - acromegaly - cardiovascular - prediction - mortality


Publication History

Article published online:
23 December 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Crisafulli S, Luxi N, Sultana J. et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol 2021: EJE-21-0216.R1. doi: 10.1530/EJE-21-0216. Epub ahead of print. PMID: 34061771
    PubMed
  • 2 Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355: 2558-2573
    CrossrefPubMedGoogle Scholar
  • 3 Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 2018; 179: 59-71
    CrossrefPubMedGoogle Scholar
  • 4 Gatto F, Campana C, Cocchiara F. et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Dis 2019; 20: 365-381
    CrossrefPubMedGoogle Scholar
  • 5 Cannavò S, Almoto B, Cavalli G. et al. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 2006; 91: 3766-3772
    CrossrefPubMedGoogle Scholar
  • 6 Ragonese M, Alibrandi A, Di Bella G. et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine 2014; 47: 206-212
    PubMedGoogle Scholar
  • 7 Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol 2001; 54: 137-154
    CrossrefPubMedGoogle Scholar
  • 8 Bogazzi F, Lombardi M, Strata E. et al. High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol 2008; 68: 361-368
    CrossrefPubMedGoogle Scholar
  • 9 Agatston AS, Janowitz WR, Hildner FJ. et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832
    CrossrefPubMedGoogle Scholar
  • 10 Ahmed W, de Graaf MA, Broersen A. et al. Automatic detection and quantification of the agatston coronary artery calcium score on contrast computed tomography angiography. Int J Cardiovasc Imaging 2015; 31: 151-161
    CrossrefPubMedGoogle Scholar
  • 11 D’Agostino RBSr, Vasan RS, Pencina MJ. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753
    CrossrefPubMedGoogle Scholar
  • 12 Hess G, Moecks J, Zdunek D. N-terminal-proBNP (NT-proBNP) as an indicator of cardiac dysfunction. A study in patients with suspected cardiac disorders. ZS Kardiologie 2005; 94: 247-254
    CrossrefPubMedGoogle Scholar
  • 13 Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004; 6: 63-70
    CrossrefPubMedGoogle Scholar
  • 14 Maisel AS, Krishnaswamy P, Nowak RM. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167
    CrossrefPubMedGoogle Scholar
  • 15 Mukoyama M, Nakao K, Saito Y. et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990; 323: 757-758
    CrossrefPubMedGoogle Scholar
  • 16 de Lemos JA, Morrow DA, Bentley JH. et al. The prognostic value of B- type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021
    CrossrefPubMedGoogle Scholar
  • 17 Morrow DA, de Lemos JA, Sabatine MS. et al. Evaluation of B-type natriuretic peptide for risk assessment in Unstable Angina/Non–ST elevation myocardial infarction: B-type natriuretic peptide and prognosis in TAC TICS-TIMI 18. J Am Coll Cardiol 2003; 41: 1264-1272
    CrossrefPubMedGoogle Scholar
  • 18 Arikan S, Bahceci M, Tuzcu A, Gokalp D. N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly. J Endocrinol Invest 2010; 33: 571-575
    CrossrefPubMedGoogle Scholar
  • 19 Andreassen M, Faber J, Kjær A, Petersen CL, Kristensen LØ. Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary 2010; 13: 329-336
    CrossrefPubMedGoogle Scholar
  • 20 Eichner M, Wallaschofski H, Schminke U. et al. Relation of IGF-1 with subclinical cardiovascular markers including intima-media thickness, left ventricular mass index and NT-proBNP. Eur J Endocrinol 2020; 182: 79-90
    CrossrefPubMedGoogle Scholar
  • 21 Melmed S, Bronstein MD, Chanson P. et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 2018; 14: 552-561
    CrossrefPubMedGoogle Scholar
  • 22 Melmed S, Casanueva FF, Klibanski A. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013; 16: 294-302
    CrossrefPubMedGoogle Scholar
  • 23 Aulinas A, Crespo I, Viladés D. et al. Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. Clin Endocrinol 2017; 86: 214-222
    CrossrefPubMedGoogle Scholar
  • 24 Campbell DJ. Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?. Clin Exp Pharmacol P 2008; 35: 442-446
    CrossrefPubMedGoogle Scholar
  • 25 Potter BJ, Beauregard C, Serri O. Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR. Pituitary 2008; 11: 49-53
    CrossrefPubMedGoogle Scholar
  • 26 Verhelst J, Velkeniers B, Maiter D. et al. Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur J Endocrinol 2013; 168: 177-184
    CrossrefPubMedGoogle Scholar
  • 27 Ito M, Kodama M, Tsumanuma I. et al. Relationship between insulin-like growth factor-I and brain natriuretic peptide in patients with acromegaly after surgery. Circulation 2007; 71: 1955-1957
    CrossrefPubMedGoogle Scholar
  • 28 Andreassen M, Faber J, Vestergaard H. et al. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol 2007; 66: 619-625
    CrossrefPubMedGoogle Scholar
  • 29 Wallaschofski H, Saller B, Spilcke-Liss E. et al. Effects of growth hormone treatment on B-type natriuretic peptide as a marker of heart failure in adults with growth hormone deficiency. Horm Metab Res 2006; 38: 656-661
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Gruson D, Alexopoulou O, Pasquet A. et al. Impact of growth hormone (GH) treatment on circulating NT-proBNP concentrations and on cardiac function in adult GH deficient patients. Scand J Clin Lab Inv 2012; 72: 387-394
    CrossrefPubMedGoogle Scholar
  • 31 Berg C, Petersenn S, Walensi M. et al. Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population. Exp Clin Endocrinol Diabetes 2013; 121: 125-132
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Ronchi CL, Varca V, Beck-Peccoz P. et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocr Metab 2006; 91: 121-128
    CrossrefPubMedGoogle Scholar
  • 33 Colao A, Pivonello R, Galderisi M. et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocr Metab 2008; 93: 2639-2646
    CrossrefPubMedGoogle Scholar